5个月脱产学习机器人系统运维，健身教练转行投身工业机器人领域……当前，越来越多年轻人选择"回 炉重造"，通过重返职校或参加企业定向培训班，系统学习某项技能，提升就业竞争力。 （摘编自《湖北日报》，原题为《"回炉重造"是为了系统升级》） 《 人民日报 》（ 2025年08月27日 05 版） (责编：杨光宇、胡永秋) "回炉"一词，常带着重新打磨的意味。当下的"回炉"，成了一种"反向镀金"。以"回炉"的年轻人姜欣茜 为例，毕业于重庆交通大学的她拥有扎实的理论基础，却因为缺少实操经验而在求职中碰壁。进入相关 学校学习机器人系统运维，考核通过后将直接入职提供培训的企业——"回炉"成为一种错位竞争、突破 职业瓶颈的策略。 终身学习是一种理念，伴随人的一生。当下趋势，正是这一理念的生动印证。学习不再止步于获得一纸 文凭，而是贯穿一生的持续投资。许多年轻人发现，一项符合市场需求的技能，可以带来明确的岗位、 清晰的上升通道、可预期的收入，这是一种基于现实考量的价值重估。与其依赖"老本"，不如主动拥抱 变化，学习人工智能、工业机器人等前沿实用技能，用与时俱进的能力赢得未来。 值得注意的是，文凭与技能并非对立关系。文凭代表着系 ...

Group 1 - Zhang Teng, the fund manager of Yinhua Ruihe, adopts a unique energy perspective and macro framework for cyclical investment, distinguishing himself from traditional value and growth investors [1][2] - His investment philosophy emphasizes capturing structural opportunities through a deep understanding of energy dynamics and macroeconomic slow variables, particularly in the context of carbon neutrality and anti-involution [1][6] - Zhang's approach to cyclical stocks focuses on underlying variables rather than merely following commodity prices, aiming to identify undervalued elastic factors at the intersection of industry logic and macro changes [1][3] Group 2 - Zhang Teng's investment framework is influenced by Taleb's "anti-fragile" theory, which emphasizes the importance of macro awareness and diversified investments to achieve long-term stability [4][5] - His strategy includes maintaining a diversified portfolio across five main sectors to mitigate risks while focusing on core driving factors of different assets [5][6] - The "anti-fragile" framework has evolved to enable the identification of opportunities during extreme market fluctuations, allowing for dynamic optimization of investment portfolios [6][8] Group 3 - In the context of the "anti-involution" policy, Zhang Teng identifies significant investment opportunities in the changing supply-demand dynamics of the non-ferrous and chemical sectors, rather than in highly discussed areas like photovoltaics [7][8] - He emphasizes the importance of focusing on industries with steep supply curves and high cost differentials, particularly in strategic resources like rare earths, which are expected to experience value reassessment [7][8] - Zhang's macro perspective includes viewing the Federal Reserve's interest rate cut cycle as a key slow variable that will benefit the non-ferrous sector, with different metals responding at varying paces [8]

8月22日晚间，东风汽车集团股份有限公司发布公告称，子公司岚图汽车将以介绍上市方式登陆港股， 东风集团股份将同步完成私有化退市。根据公告，本次交易采用"股权分派+吸收合并"的组合模式，总 体收购价格为10.85港元/股。其中现金对价6.68港元/股，岚图股权对价4.17港元/股。 如果岚图汽车港股成功上市，将成为继蔚来、小鹏、理想、零跑、赛力斯、小米之后，又一家登陆港股 的新能源汽车企业。 更为关键的是，东风集团这场"腾笼换鸟"的资本运作，不仅关系到一家央企的转型命运，更将成为传统 汽车制造商在新能源时代如何通过资本创新实现价值重估的重要案例。 图 片来源：岚图汽车官网 介绍上市的资本考量 介绍上市是已发行证券申请上市的一种方式，核心特点是不在上市时发行新股或涉及融资，仅将现有股 东持有的证券在交易所挂牌交易。这种上市方式适合已经有一定规模、不需要立即融资但希望提升流动 性和品牌形象的企业。 资本市场的突围选择 东风集团的港股低估值困境已持续多年。截至2025年7月31日，东风集团总市值为391.2亿港币，收盘价 为4.74港元/股，PB仅为0.24倍，市值长期远低于净资产。 受制于估值情况，东风集团股份上市 ...

8月22日，A股上涨，沪指突破3800点，再创10年新高。 沪指日K走势图 多重利好共振下的资产价值重估 2025年，全球资本配置正在悄悄发生转变，美元走弱等不 确定性推动资金从美国市场流向估值洼地，而中国因经济韧性 与产业红利，成为外资增配的主要目的地之一。 国内政策积极发力对资本市场形成双重驱动。在"更加积极 有为的宏观政策"持续发力下，2025年上半年，中国经济顶住外 部压力实现5.3%的GDP增速，展现出超预期的韧性。另一方 面，央行通过降准降息等工具保持流动性合理充裕。产业新动 能加速壮大，AI硬件和大模型、机器人以及创新药等新质生产 力加速成长，成为吸引外资的新磁极。 在这轮由"政策托底+科技突破"共同驱动的价值重估中，外 资对中国资产的态度正从"可交易"转向"可投资" ，北向资金上 半年净流入超800亿元，折射出国际资本对中国经济转型升级的 长期信心。 估值修复叠加资金回流，中国资产成为美元流动性外溢的 价值洼地。 2025年伊始，美国经济不确定性大幅上升，在欧洲加速财 政刺激的背景下，美国经济的相对优势削弱，在美元走弱的驱 动下，资金开始流向美国以外地区。摩根大通资产管理公司指 出："从估值角 ...

Investment Rating - The investment rating for the company is "Buy" for both A-shares and H-shares, maintained from previous assessments [7]. Core Views - The company reported better-than-expected performance in its interim results, with a proposed interim dividend of 0.1 CNY per share, totaling 836 million CNY, representing a payout ratio of 24.77% [1]. - The company anticipates a revaluation of its value due to the compliance and confirmation of national subsidies [4]. - The company has adjusted its profit forecasts slightly downward for 2025-2027, with a projected compound annual growth rate (CAGR) of 10.1% for net profit [5]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved revenue of 15.657 billion CNY, a year-on-year decrease of 18.6%, and a net profit attributable to shareholders of 3.375 billion CNY, down 13.8% year-on-year [1]. - The second quarter saw revenue of 7.517 billion CNY, a year-on-year decrease of 18.2% and a quarter-on-quarter decrease of 7.7% [1]. Installed Capacity and Generation - The company added 2,053.54 MW of installed capacity in the first half of 2025, bringing the total to 43.197 GW, with wind power contributing 986.95 MW and solar power 1,096.59 MW [2]. - The company's electricity generation increased by 12.7% year-on-year, with wind power generation up 6.1% to 33,502 GWh, primarily due to new installations [2]. Profitability Analysis - The operating profit from the wind power segment decreased by 11% year-on-year to 6.213 billion CNY, with a corresponding profit per MWh down 16% to 185 CNY/MWh [3]. - The photovoltaic segment saw a 51% increase in operating profit to 550 million CNY, with a profit per MWh of 89 CNY/MWh, down 12% year-on-year [3]. Cash Flow and Receivables - As of June 2025, the company's receivables financing increased by 5.96 billion CNY compared to the beginning of the year, accounting for 55.7% of net assets, indicating a rising trend since the end of 2022 [4]. - The operating cash flow for the first half of 2025 decreased by 8.5% year-on-year to 6.673 billion CNY, but the second quarter saw a year-on-year increase of 7.3% to 3.977 billion CNY [4]. Valuation Adjustments - The target price for A-shares is adjusted to 18.72 CNY, down from 18.96 CNY, based on a 24x PE for 2025, while the target price for H-shares is adjusted to 7.63 HKD from 7.73 HKD, based on a 9x PE for 2025 [5].

Market Overview - The A-share market indices collectively rose this week, with the Shanghai Composite Index reaching a new high for the year, increasing over 2% [1] - The Shenzhen Component and ChiNext indices saw weekly gains of 1.25% and 0.49%, respectively [1] - The upward trend of the market is supported by liquidity and ongoing policy measures, which are expected to optimize supply and demand dynamics [1] Economic Indicators - In July, the Consumer Price Index (CPI) rose by 0.4% month-on-month, reversing a previous decline of 0.1% [2] - The core CPI, excluding food and energy, increased by 0.8% year-on-year, marking a continuous expansion for three months [2] - The Producer Price Index (PPI) decreased by 0.2% month-on-month, with a year-on-year decline of 3.6% [2] Investment Insights - Dongwu Securities indicates a solid upward trend in the market, with expectations for overall profitability and return on equity (ROE) to stabilize and improve [4] - The market is shifting from traditional cyclical sectors to technology sectors, with a focus on high-quality technology assets that may yield significant excess returns in Q3 [5][9] - Open-source Securities highlights a "dual-driven" market theme, with increasing margin financing balances and a clearer market direction driven by technology and PPI trading [6] Sector Focus - Investment opportunities are emerging in technology sectors such as AI, robotics, and high-end manufacturing, as well as in defensive high-dividend sectors [7][8] - Allianz Fund anticipates significant excess returns for quality technology assets in Q3, driven by a new cycle of value reassessment in the A-share market [9] - Citic Prudential Fund emphasizes the certainty of opportunities in manufacturing companies, particularly those with improving profitability and relatively low valuations [10]

Group 1: Policy and Market Response - The Central Financial Committee's recent meeting emphasized the need to regulate low-price disorderly competition among enterprises and promote product quality improvement [1] - In response to the "anti-involution" policy, industries such as photovoltaic, cement, steel, and coke have begun to reduce production and increase prices [1][4] - The National Development and Reform Commission and the State Administration for Market Regulation have proposed amendments to the Price Law to standardize market pricing and address "involution-style" competition [1][4] Group 2: Commodity Market Trends - Major commodity futures, including coking coal, coke, polysilicon, industrial silicon, glass, and soda ash, have seen significant price increases, with polysilicon rising by 50% in July and reaching a record high of 53,000 yuan/ton [1][4] - The market is experiencing a shift from "anti-involution driven" to "stock replenishment driven," with expectations of further price increases as downstream demand rises [4][5] - Analysts predict that most commodity futures will experience a comprehensive rebound in the third quarter, driven by policy support and improved market conditions [5] Group 3: Industry Challenges and Opportunities - The chemical industry is facing a cycle of low-price competition, which undermines profitability and restricts R&D investment, leading to a lack of product value enhancement [2] - The Ministry of Industry and Information Technology is set to introduce plans to stabilize growth in key industries, focusing on structural adjustments and the elimination of outdated production capacity [2][3] - The "anti-involution" policy aims to enhance market order and promote industry upgrades, directing resources towards high-efficiency sectors and improving global competitiveness [6]

Macro News - The issuance of new local government special bonds has accelerated since April, with a record high of 616.936 billion yuan in July, an increase of 89.842 billion yuan from the previous month [1] - The cumulative issuance of new special bonds reached 2.16 trillion yuan in the first half of the year, a significant year-on-year increase of 45%, supporting major project construction and maintaining resilience in infrastructure investment growth [1] - The China Logistics and Purchasing Federation reported that the commodity price index rose for three consecutive months, reaching 111.4 points in July, a month-on-month increase of 0.5% [1] - Among 50 monitored commodities, 32 saw price increases, with lithium carbonate, industrial silicon, and coking coal rising by 10.2%, 9.8%, and 9.6% respectively [1] Industry News - The China Real Estate Industry Association announced measures to support the healthy development of small and medium-sized real estate companies, including reflecting policy demands, providing financial services, promoting sales, and improving supply chains [3] - The National Healthcare Security Administration is optimizing drug procurement measures, with 55 drugs proposed for inclusion in the national procurement range [3] - The paper industry is experiencing a price increase, with leading companies like Nine Dragons Paper and Lee & Man Paper announcing price hikes starting August 1, marking the fourth round of price increases since July [4] - Rising costs of raw materials, energy, and logistics are driving this price increase, which is seen as a response to the declining market conditions earlier this year [4] Sector Insights - CITIC Securities reports that the liquor industry is rapidly bottoming out, with leading companies likely to benefit from channel adjustments and market expansion as consumer demand gradually improves [5] - The beer industry is expected to maintain steady growth in sales, with an estimated revenue growth rate of 2%-5% [5] - China International Capital Corporation highlights the trend towards lightweight humanoid robots, which can enhance performance and safety through material and structural optimizations [5] - Huatai Securities expresses optimism about the commercial real estate sector, noting that top operators' shopping center assets exceed their book value, with C-REITs providing a clearer path for value realization [6]

Group 1 - A-shares opened collectively higher with the Shanghai Composite Index up 0.15%, Shenzhen Component Index up 0.34%, and ChiNext Index up 0.65% [1] - CPO, HBM, and Zhongbing system sectors showed significant gains [1] Group 2 - CITIC Securities interprets the recently issued "Implementation Plan for the Childcare Subsidy System" as a measure to support families in raising infants and toddlers, which may help improve birth rates [2] - The market showed cautious expectations regarding the effectiveness of the subsidy policy, with related sectors such as dairy, maternal and infant products, and toys experiencing initial gains followed by slight declines [2] Group 3 - Huatai Securities expresses optimism about the commercial real estate sector under a value reassessment logic, noting that leading operators' shopping center assets exceed their book value [3] - The C-REITs channel facilitates the realization of this value, enhancing liquidity and making valuations more meaningful [3] Group 4 - CICC highlights multiple macroeconomic factors supporting the performance of the Chinese stock market despite the need for improvement in economic indicators [4] - Confidence in China's medium to long-term economic outlook has improved since last year's fourth quarter, particularly due to positive effects from DeepSeek [4] - The declining proportion of real estate in the economy has reduced its negative impact, and policymakers are increasingly focused on the economy, stock market, and real estate market [4] - There is a rising motivation among residents to allocate to risk assets, especially equities, due to limited returns on safe assets [4] - Future policies addressing debt issues are crucial for enhancing economic vitality and capital market significance [4]

Core Viewpoint - The innovative pharmaceutical sector has emerged as the "most shining track" in the capital market for the first half of 2025, with the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index achieving a year-to-date increase of 97.01%, marking the highest half-year growth since 2018 [1] Group 1: Company Performance - By the first half of 2025, the company reported revenue exceeding RMB 6 billion, a year-on-year increase of over 50%, and net profit ranging from RMB 42.7 million to RMB 52.7 million, marking a continuous profit validation [1][3] - The company's stock price surged by 209.88% year-to-date, outperforming both the Hang Seng Healthcare Index and the Hang Seng Index [1] Group 2: Strategic Transformation - The company has transitioned its revenue structure from "service infusion" to "product self-sustenance," indicating a successful shift towards high-value products and validating the commercial viability of its technology [3] - The company has established a global presence, enhancing its local service capabilities through the expansion of its Boston laboratory and securing collaborations with top 10 multinational pharmaceutical companies [4] Group 3: Operational Efficiency - The company increased its R&D expenditure to approximately RMB 206.1 million to RMB 216.1 million, a year-on-year increase of about 30%, while optimizing its management structure and digitalizing production processes to enhance operational efficiency [5] - The company achieved net profit for two consecutive reporting periods, indicating the establishment of a commercial flywheel effect from R&D investment to product revenue and profit accumulation [5] Group 4: Market Opportunities - Recent policy measures from the National Healthcare Security Administration and the National Health Commission support the high-quality development of innovative drugs, creating a favorable environment for companies like the subject firm [6] - The capital market's evaluation logic for innovative pharmaceutical companies has fundamentally changed, with a shift from "story-driven" to "performance-driven" valuation, enhancing confidence in profitability [7] Group 5: Globalization and Future Growth - The company is positioned as a significant contributor to the global pharmaceutical pipeline, particularly in the ADC (antibody-drug conjugate) field, and ranks among the top three in terms of outbound licensing transactions [8] - The company's unique technology platforms and innovative antibody assets are expected to establish it as a "technical arms dealer" in the global pharmaceutical landscape, potentially leading to a dual growth trajectory [8] Conclusion - The company is poised for a significant transformation from a follower to a leader in the global innovative drug sector, with its recent profitability breakthrough marking just the beginning of its growth journey [9][10]